2023
Patent Ductus Arteriosus and Development of Bronchopulmonary Dysplasia-associated Pulmonary Hypertension.
Gentle S, Travers C, Clark M, Carlo W, Ambalavanan N. Patent Ductus Arteriosus and Development of Bronchopulmonary Dysplasia-associated Pulmonary Hypertension. American Journal Of Respiratory And Critical Care Medicine 2023, 207: 921-928. PMID: 36378949, PMCID: PMC10111998, DOI: 10.1164/rccm.202203-0570oc.Peer-Reviewed Original ResearchConceptsBPD-associated pulmonary hypertensionPatent ductus arteriosusDuctus arteriosus patencyPreterm infantsBronchopulmonary dysplasiaPostnatal dayDuctus arteriosusPulmonary hypertensionRespiratory supportModerate to large patent ductus arteriosusBronchopulmonary dysplasia-associated pulmonary hypertensionPreterm infants of gestational ageInfants of gestational ageRetrospective case-control studyEvolving bronchopulmonary dysplasiaExtremely preterm infantsCase-control studyModifiable risk factorsGestational ageDuctal patencyComposite outcomeControl subjectsRisk factorsInfantsPatency
2018
Caffeine controversies
Gentle S, Travers C, Carlo W. Caffeine controversies. Current Opinion In Pediatrics 2018, 30: 177-181. PMID: 29346141, DOI: 10.1097/mop.0000000000000588.Peer-Reviewed Original ResearchMeSH KeywordsApneaBronchopulmonary DysplasiaCaffeineCentral Nervous System StimulantsDrug Administration ScheduleDuctus Arteriosus, PatentHumansInfant, NewbornInfant, PrematureConceptsApnea of prematurityBronchopulmonary dysplasiaPreterm infantsEvidence of bronchopulmonary dysplasiaCaffeine usePatent ductus arteriosusRate of motor impairmentCaffeine therapyRate of deathRandomized controlled trialsDuctus arteriosusNeurodevelopmental impairmentTherapy initiationNeonatal careCaffeine groupFollow-upTiming of initiationInfantsPretermCaffeineDoseMotor impairmentRisk reductionImpairmentApnea